BME Seminar - Wed., Nov. 20
|Event Date:||November 20, 2013|
|Location:||MJIS 1001, WL campus
(The seminar will be teleconferenced to SL-220 at IUPUI.)
Abstract: Vascular endothelial growth factor (VEGF) is a potent regulator of angiogenesis, and its role in cancer biology has been widely studied. Many cancer therapies target angiogenesis, with a focus being on VEGF-mediated signaling, such as antibodies to VEGF. However, it is difficult to predict the effects of VEGF-neutralizing agents. We have developed a whole-body model of VEGF kinetics and transport under pathological conditions (in the presence of breast tumor). The model includes two major VEGF isoforms VEGF121 and VEGF165, receptors VEGFR1, VEGFR2 and co-receptors Neuropilin-1 and Neuropilin-2. We have also profiled the levels of these receptors on endothelial cells, and parenchymal cells (muscle fibers and tumor cells), and incorporated these experimental data into our models. Through this integrative approach, we investigate the action of VEGF-neutralizing agents (called “anti-VEGF”) in the treatment of cancer.
Bio available at: http://publish.illinois.edu/systemsbio/people/faculty/
~BME Faculty Host: Sherry Voytik-Harbin~
***Coffee and juice will be provided at West Lafayette***